期刊文献+

达比加群对非瓣膜性心房颤动患者抗凝的临床观察 被引量:5

原文传递
导出
摘要 非瓣膜性持续性心房颤动(简称房颤)患者70例,在常规治疗基础上,进行抗凝治疗,随机分成两组,观察组34例应用达比加群治疗(每次110mg,2次/日),对照组36例应用华法林,维持患者国际正常化比率2.0~3.0,随访2年。观察组左房血栓形成包括云雾状改变、卒中的发生率分别为7.14%、3.57%,对照组分别为17.86%、8.33%(P〈0.01);观察组出血事件的发生率3.57%,对照组则为4.17%(P〉0.05)。结论:达比加群可以明显降低非瓣膜性持续性房颤患者左房血栓形成和卒中的发生率。
作者 杨国康 谢彬
出处 《中国心脏起搏与心电生理杂志》 2014年第6期550-550,共1页 Chinese Journal of Cardiac Pacing and Electrophysiology
  • 相关文献

参考文献1

  • 1Waks JW,Zimetbaum PJ.Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation:the RE-LY study and substudies with commentary[J].Expert Rev Cardiovasc Ther,2013,11(11):1 461.

同被引文献53

  • 1Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in at rial fibrillation. The Framingham Study[J]. Stroke, 1996,27 (10) :1 760.
  • 2January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibril- lation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practiceguidelines and the Heart Rhythm Society[J]. Circulation,2014, 130(23) z2 071.
  • 3Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12),1 139.
  • 4Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation [J].N Engl J Med, 2011, 365(10):883.
  • 5Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med,2011, 365(11) :981.
  • 6Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ ECAS expert consensus statement on catheter and surgical abla- tion of atrial fibrll].ation: recommendations for patient selection, procedural techniques, patient management and follow-up, defi- nitions, endpoints, and research trial design [J]. Heart Rhythm,2012,9(4) : 632.
  • 7Winkle RA, Mead RH, Engel G, et al. The use of dabigatran immediately after atrial fibrillation ablation[J]. J Cardiovasc Electrophysiol,2012, 23(3) :264.
  • 8Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periproeedural anticoag- ulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry[J]. J Am Coil Cardiol,2012, 59(13):1 168.
  • 9Haines DE, Mead-Salley M, Salazar M, et al. Dabigatran ver-sus warfarin anticoagulation before and after catheter ablation for the treatment of atrial fibrillation[J]. J Interv Card Electro- physiol, 2013,37(3) ..233.
  • 10Maddox W, Kay GN, Yamada T, et al. Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation [J]. J Cardiovasc Electrophysiol, 2013,24 (8) :861.

引证文献5

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部